Abstract
In recent years Immune Check Point Inhibitors (ICIs) have played an integral role in the treatment of a wide variety of malignancies. Despite improvements in survival outcomes with immunotherapy, immune related Adverse Events (irAEs) are increasing in incidence
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have